Citation Impact
54 standout
Citing Papers
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
2024 Standout
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
2024 Standout
Works of Zahi Mitri being referenced
SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.
2020
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
2019
Author Peers
| Author | Oncology | PRM | Cancer Research | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Zahi Mitri | 448 | 243 | 168 | 291 | 46 | 855 | |
| Lorraine Weller Clarke | 3 | 10 | 525 | ||||
| Tarik Bereket | 4 | 2 | 16 | 389 | |||
| Janelle M. Landau | 104 | 20 | 81 | 532 | 9 | 1.6k | |
| D. M. Kuehn | 12 | 614 | |||||
| M. Erkinjuntti | 6 | 126 | 17 | 91 | 22 | 518 |
All Works
Login with ORCID to disown or claim papers
Loading papers...